Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 25;203(1):53.
doi: 10.1007/s00408-025-00801-x.

Update 2025: Management of Non‑Small-Cell Lung Cancer

Hyein Jeon  1   2   3 , Shuai Wang  1   2   3 , Junmin Song  4 , Harjot Gill  5 , Haiying Cheng  6   7   8
Affiliations
Review

Update 2025: Management of Non‑Small-Cell Lung Cancer

Hyein Jeon et al. Lung. .

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide. Since 2024, the non-small-cell lung cancer (NSCLC) landscape has undergone a transformative shift, driven by 11 FDA approvals. Recent advances in molecular profiling, targeted therapies, and immunotherapies have revolutionized NSCLC management, ushering in an era of personalized treatment with improved patient outcomes. The increased adoption of low-dose computed tomography (LDCT) for screening has enhanced early detection, enabling intervention at more curable stages. Molecular diagnostics now play a pivotal role in guiding treatment strategies, with actionable genomic alterations (AGAs) informing the use of EGFR, ALK, ROS1, KRAS, NRG1, and other targeted inhibitors in both early and advanced settings. For instance, targeted therapies are increasingly being integrated into early-stage management, with adjuvant osimertinib for EGFR-mutated NSCLC and alectinib for ALK-positive NSCLC demonstrating substantial survival benefits. Immunotherapy, particularly immune checkpoint inhibitors, has become a cornerstone of treatment for AGA-negative NSCLC, either as monotherapy or in combination with chemotherapy, and is increasingly being utilized in the perioperative setting. Furthermore, emerging therapies such as bispecific antibodies, antibody-drug conjugates (ADCs), and novel immunotherapeutic agents show promise in addressing resistance mechanisms and improving outcomes in advanced-stage disease. Although new challenges arise, the evolving NSCLC treatment paradigm continues to prioritize precision medicine, offering hope for prolonged survival and enhanced quality of life for patients.

Keywords: Actionable Genomic Alterations; Immunotherapy; Lung Cancer Management; NSCLC; Targeted Therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Simplified schematic of initial management of NSCLC. AGA actionable genomic alterations, CIO chemoimmunotherapy, CT chemotherapy, IO immunotherapy, NSCLC non-small-cell lung cancer
See this image and copyright information in PMC

References

    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2024, 74(3):229–263. - PubMed
    1. Siegel RL, Miller KD, Wagle NS, Jemal A: Cancer statistics, 2023. CA: A Cancer Journal for Clinicians 2023, 73(1):17–48. - PubMed
    1. Team TNLSTR: Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. New England Journal of Medicine 2011, 365(5):395–409. - PMC - PubMed
    1. Moyer VA: Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine 2014, 160(5):330–338. - PubMed
    1. Wender R, Fontham ETH, Barrera E, Colditz GA, Church TR, Ettinger DS, Etzioni R, Flowers CR, Scott Gazelle G, Kelsey DK et al: American Cancer Society lung cancer screening guidelines. CA: A Cancer Journal for Clinicians 2013, 63(2):106–117. - PMC - PubMed

MeSH terms

Substances